U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula 2C4H5NO4.Mg.2H.4H2O
Molecular Weight 360.5556
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MAGNESIUM ASPARTATE

SMILES

[H+].[H+].O.O.O.O.[Mg++].N[C@@H](CC([O-])=O)C([O-])=O.N[C@@H](CC([O-])=O)C([O-])=O

InChI

InChIKey=CRSJYWPXKKSOCQ-CBAPHJFVSA-L
InChI=1S/2C4H7NO4.Mg.4H2O/c2*5-2(4(8)9)1-3(6)7;;;;;/h2*2H,1,5H2,(H,6,7)(H,8,9);;4*1H2/q;;+2;;;;/p-2/t2*2-;;;;;/m00...../s1

HIDE SMILES / InChI
Molecular Formula Mg
Molecular Weight 24.305
Charge 2
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula H2O
Molecular Weight 18.0153
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula H
Molecular Weight 1.0079
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula C4H5NO4
Molecular Weight 131.0868
Charge -2
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Sources: https://www.scbt.com/scbt/product/magnesium-nitrate-hexahydrate-13446-18-9 | https://www.ncbi.nlm.nih.gov/pubmed/18964415 | https://www.ncbi.nlm.nih.gov/pubmed/2843308http://dx.doi.org/10.1155/2015/498932 | http://iicbe.org/upload/4152C514072.pdfhttps://www.ncbi.nlm.nih.gov/pubmed/351265https://www.ncbi.nlm.nih.gov/pubmed/15480451 | https://www.scbt.com/scbt/product/magnesium-iodide-10377-58-9https://hazmap.nlm.nih.gov/category-details?table=copytblagents&id=1640https://www.drugs.com/dosage/magnesium-lactate.htmlhttps://www.xymogen.com/assets/imageDisplay.ashx?productID=111&attachmentTypeID=1https://www.drugs.com/ppa/magnesium-chloride.htmldoi: 10.1081/SCC-120022479https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020309s028lbl.pdfhttp://onlinelibrary.wiley.com/doi/10.2903/j.efsa.2013.3444/pdfDOI: 10.2903/j.efsa.2008.883http://www.internationalcrystal.net/optics_11.htm | https://www.ncbi.nlm.nih.gov/pubmed/27792982 | https://www.ncbi.nlm.nih.gov/pubmed/26952467 | https://www.ncbi.nlm.nih.gov/pubmed/27995243http://www.sciencedirect.com/science/article/pii/004484868990080Xhttp://www.db-pharma.com/anglais/49.pdf
Curator's Comment: description was created based on several sources, including: http://www.medicatione.com/?c=drug&s=delbiase&ingredient=magnesium%20bromide/magnesium%20chloride | DOI: 10.1002/0471238961.0218151310010311.a02 | http://mon-naturopathe.com/blog/techniques-naturopathiques/chlorure-de-magnesium-et-delbiase

Magnesium bromide is a small colorless crystal used as an anticonvulsant, a cathartic, and an electrolyte replenisher in the treatment of pre-eclampsia and eclampsia. It causes direct inhibition of action potentials in myometrial muscle cells. Also it is recommended for magnesium deficiency. In case of associated calcium deficiency, treat magnesium deficiency before calcium deficiency. Magnesium bromide is used in medicine as a mild sedative for treatment of nervous disorders.

CNS Activity

Originator

Ulex, G.L.
66
Curator's Comment: Ulex, a Swedish geologist, is generally credited with introduction of the term struvite in1845

Approval Year

1921
1447
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8146
Modulator
817
Modulator
817
Modulator
817
Modulator
817
Interacts
314
Protein S100-A8
66
Target ID: P05109
Gene ID: 6279.0
Gene Symbol: S100A8
Target Organism: Homo sapiens (Human)
Binding Agent
1037
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Basic research
Unknown

Approved Use

Unknown
Primary
Preclinical
Unknown

Approved Use

Unknown
Primary
Preclinical
Unknown

Approved Use

Unknown
Preventing
Approved
8307
MAGNESIUM SULFATE

Approved Use

INDICATIONS AND USAGE Magnesium Sulfate in Water for Injection is indicated for the prevention and control of seizures in preeclampsia and eclampsia, respectively. When used judiciously it effectively prevents and controls the convulsions of eclampsia without producing deleterious depression of the central nervous system of the mother or infant. However, other effective drugs are available for this purpose.

Launch Date

7.9038723E11
Primary
Approved
8307
MAGNESIUM SULFATE

Approved Use

INDICATIONS AND USAGE Magnesium Sulfate in Water for Injection is indicated for the prevention and control of seizures in preeclampsia and eclampsia, respectively. When used judiciously it effectively prevents and controls the convulsions of eclampsia without producing deleterious depression of the central nervous system of the mother or infant. However, other effective drugs are available for this purpose.

Launch Date

7.9038723E11
Diagnostic
Approved
8307
ColPrep Kit

Approved Use

INDICATIONS AND USAGE ColPrep Kit is indicated for cleansing of the colon as a preparation for colonoscopy in adults

Launch Date

1.48279683E12
Primary
Phase III
651
MAGNESIUM SULFATE

Approved Use

INDICATIONS AND USAGE Magnesium Sulfate in Water for Injection is indicated for the prevention and control of seizures in preeclampsia and eclampsia, respectively. When used judiciously it effectively prevents and controls the convulsions of eclampsia without producing deleterious depression of the central nervous system of the mother or infant. However, other effective drugs are available for this purpose.

Launch Date

7.9038723E11
Curative
Approved
8307
MagMin

Approved Use

Magnesium aspartate (MagMin) is indicated for patients with documented hypomagnesaemia.
Curative
Not Provided
505
DELBIASE

Approved Use

Unknown
Primary
Not Provided
505
DELBIASE

Approved Use

Unknown
Primary
Not Provided
505
DELBIASE

Approved Use

Unknown
Curative
Approved
8307
Magnesium Chloride

Approved Use

Magnesium Chloride injection is indicated as an electrolyte replenisher in magnesium deficiencies
Palliative
Phase II
1133
Magnesium Chloride

Approved Use

Unknown
Palliative
Phase III
651
Magnesium Chloride

Approved Use

Unknown
Primary
Approved
8307
EPIMAG

Approved Use

Magnesium citrate is indicated in cases of oxaluria, to prevent recurrence of calcium oxalate kidney stones.
Primary
Approved
8307
EPIMAG

Approved Use

Used to relief of occasional constipation (irregularity).
Curative
Approved
8307
Magnesium Citrate

Approved Use

Magnesium citrate is indicated to supports magnesium nutritional adequacy.
Curative
Approved
8307
Unknown

Approved Use

Magnesium lactate is a naturally occurring mineral that is needed in the body to support the function of the heart, nervous system, and digestive system. Magnesium lactate is used as a mineral supplement to treat magnesium deficiency.
PubMed

PubMed

TitleDatePubMed
Struvite stones.
1978 May
Cardiopulmonary arrest due to acute maternal hypermagnesaemia.
1981 May 9
Regulation of membrane histamine H1-receptor binding sites by guanine nucleotides, mono- and divalent cations.
1986 Apr
Hypomagnesaemic tetany associated with prolonged treatment with aminoglycosides.
1986 Mar 22
Effects of the intravenous administration of magnesium sulfate on corrected serum calcium level and nephrogenous cyclic AMP excretion in normal human subjects.
1986 Nov
Metal: ATP characteristics of insulin- and epidermal growth factor-stimulated phosphorylation in detergent extracts of rat liver plasma membranes.
1986 Sep
Metabolism of magnesium and zinc in patients treated with antiepileptic drugs and with magnesium lactate.
1987
A comparison of two digestion procedures for the determination of selenium in biological material.
1987 Oct
Fluorimetry of selenium in body fluids after digestion with nitric acid, magnesium nitrate hexahydrate, and hydrochloric acid.
1988 Sep
Effect of magnesium diet in gentamicin-induced acute renal failure in rats.
1989
Cocaine-induced cerebral vascular damage can be ameliorated by Mg2+ in rat brain.
1990 Feb 5
Modulation of mu, delta and kappa opioid receptors in rat brain by metal ions and histidine.
1990 May
[Hemiparesis and torsade de pointes under low-dose sotalol therapy].
1990 Sep 22
Magnesium inhibits the hypertensive but not the cardiotonic actions of low-dose epinephrine.
1991 Jun
['Cardiac ballet' with and without amiodarone].
1993 Jan 13
Management of eclampsia.
1994 Apr
Accidental cardiopulmonary arrest following magnesium sulphate overdose.
1994 Jun 15
Conventional and Eccentric Uses of Crystallographic Databases in Practical Materials Identification Problems.
1996 May-Jun
Struvite stones.
1999
Effect of maternal tocolysis on the incidence of severe periventricular/intraventricular haemorrhage in very low birthweight infants.
2001 Jul
Contraindication of magnesium sulfate in a pregnancy complicated with late-onset diabetes mellitus and sensory deafness due to mitochondrial myopathy.
2001 Oct
Infantile renal dysfunction associated with intrauterine exposure to ritodrine and magnesium sulfate.
2002 Jun
The prevention of pain from injection of rocuronium by magnesium sulphate, lignocaine, sodium bicarbonate and alfentanil.
2003 Jun
A new fungicide produced by a Streptomyces sp. GAAS7310.
2005 Aug
Magnesium attenuates isoproterenol-induced acute cardiac dysfunction and beta-adrenergic desensitization.
2007 Mar
Characterization and distribution of the selected metals in the scalp hair of cancer patients in comparison with normal donors.
2007 Sep
[The characterization of central neuromediation in rats fed with magnesium-deprived diet before and after magnesium replenishment].
2008 Jul
Treatment of migraine with prophylactic drugs.
2008 Oct
Cocaine use disorders and serum magnesium profile.
2009
Intradermal administration of magnesium sulphate and magnesium chloride produces hypesthesia to mechanical but hyperalgesia to heat stimuli in humans.
2009 Aug 28
Differential binding of inorganic particles to MARCO.
2009 Jan
Cardiopulmonary arrest in pregnancy: two case reports of successful outcomes in association with perimortem Caesarean delivery.
2009 Sep
Increased expression of glucose transporter 3 in gerbil brains following magnesium sulfate treatment and focal cerebral ischemic injury.
2010 Jun
Carcinogenic heavy metals replace Ca2+ for DNA binding and annealing activities of mono-ubiquitinated annexin A1 homodimer.
2010 Oct 1
Magnesium imide: synthesis and structure determination of an unconventional alkaline earth imide from decomposition of magnesium amide.
2011 Feb 7
Magnesium chloride tetrahydrate, MgCl2·4H2O.
2012 Jan
Increased zinc and manganese in parallel with neurodegeneration, synaptic protein changes and activation of Akt/GSK3 signaling in ovine CLN6 neuronal ceroid lipofuscinosis.
2013
Ofloxacin induces apoptosis via β1 integrin-EGFR-Rac1-Nox2 pathway in microencapsulated chondrocytes.
2013 Feb 15
Altered biometal homeostasis is associated with CLN6 mRNA loss in mouse neuronal ceroid lipofuscinosis.
2013 Jun 15
Assessment of infantile mineral imbalances in autism spectrum disorders (ASDs).
2013 Nov 11
Cascade cyclizations of acyclic and macrocyclic alkynones: studies toward the synthesis of phomactin A.
2013 Oct 4
Effects of three kinds of organic acids on phosphorus recovery by magnesium ammonium phosphate (MAP) crystallization from synthetic swine wastewater.
2014 Apr
A comparison of oral sulfate solution with sodium picosulfate: magnesium citrate in split doses as bowel preparation for colonoscopy.
2014 Dec
Precipitation of amorphous magnesium ammonium phosphate: is it a precursor for staghorn stones?
2014 Jun
Randomized controlled trial of low-volume bowel preparation agents for colonic bowel preparation: 2-L polyethylene glycol with ascorbic acid versus sodium picosulfate with magnesium citrate.
2015 Feb
Polyethylene glycol plus ascorbic acid is as effective as sodium picosulfate with magnesium citrate for bowel preparation: A randomized trial.
2016 Apr
Superiority of a Split-dose Regimen of Sodium Picosulfate/Magnesium Citrate (SPMC) in Comparison to a Prior-day Schedule (AM/PM) for Colonoscopy Preparation. A Randomized Single-blinded Study.
2016 Sep
High power rechargeable magnesium/iodine battery chemistry.
2017 Jan 10
MgI(2) -chemoselective cleavage for removal of amino acid protecting groups: A fresh vision for peptide synthesis.
2017 Mar
Effect of power ultrasound on crystallization characteristics of magnesium ammonium phosphate.
2017 May
Patents

Patents

03931199
71
03931205
80
03931302
69
03932463
70
03932472
92
03932479
112
03932483
74
03932524
68
03933824
70
03935253
66
03935271
69
03936470
98
03939091
68
03944589
66
03950406
119
03950427
70
03950525
67
03957788
66
03960906
66
03960907
67
03961066
66
03963724
66
03965143
66
03966648
67
03966773
136
03968231
67
03969368
66
03969384
66
03973022
77
03973030
67
03978121
80
03978129
66
03978130
66
03980795
66
03981917
80
03982001
66
03983164
67
03985729
66
03985817
66
03987009
96
03987091
67
03988205
66
03989724
70
03989749
68
03989841
66
03991106
66
03993773
66
03994961
66
03995054
67
03995056
70
03998834
69
04005147
106
04045433
67
04059595
66
04088772
67
04144333
66
04156786
66
04289816
66
04341767
67
04454357
66
04471070
66
04540815
66
04546195
66
04569941
66
04577011
67
04585885
67
04599341
66
04661260
68
04725688
68
04734420
73
04916235
70
04935430
66
04990319
66
05012019
66
05177240
66
05206229
66
05275950
67
05326548
66
05389640
67
05451591
67
05633237
66
05658908
68
05719148
82
05786353
67
05859290
66
05929067
67
06017928
88
06040331
66
06051712
73
06100275
67
06150526
72
06156767
66
06274737
68
06380218
73
06540905
67
06613708
66
06812355
66
07230017
69
07402595
70
07445915
66
07557213
67
07601736
66
07691842
69
08236943
66
08383835
66
20050130276
66
20060100207
66
20100267970
66
CN106582743
66
DE1110825
66
EP1810974A1
66
EP2259773A1
66
EP2708510A1
66
EP2714042A1
66
US1913539
66
US20060083725
66
US20140076804
66
US2034070
66
US2260004
66
US2877095
66
US3030184
66
US3320048
66
US3377271
66
US3429777
66
US3476510
66
US3760050
66
US3994859
66
US4111835
66
US4535183
66
US4748283
66
US4959222
66
US7182872
66
US7608239
66
US9334166
66
WO2000050046A1
66
WO2005123647A1
68

Sample Use Guides

In Vivo Use Guide
Curator's Comment: Magnesium Chloride
Unknown
Route of Administration: Unknown
In Vitro Use Guide
Curator's Comment: Magnesium Chloride
Unknown
Substance Class Chemical
Created
by admin
on Sat Dec 17 11:20:46 UTC 2022
Edited
by admin
on Sat Dec 17 11:20:46 UTC 2022
Record UNII
R17X820ROL
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
MAGNESIUM ASPARTATE
II   INCI   MART.   VANDF  
INCI  
Official Name English
MAGNESIUM ASPARTATE [VANDF]
Common Name English
MAGNESIUM ASPARTATE [INCI]
Common Name English
MAGNESATE(2-), BIS(L-ASPARTATO(2-)-.KAPPA.N,.KAPPA.O1)-, DIHYDROGEN, (T-4)-
Common Name English
DIHYDROGEN BIS(L-ASPARTATO(2-)-N,O1)MAGNESATE(2-)
Common Name English
(+)-MAGNESIUM ASPARTATE TETRAHYDRATE
Systematic Name English
ASPARTIC ACID, MAGNESIUM SALT (2:1), TETRAHYDRATE, L-
Common Name English
Magnesium aspartate tetrahydrate [WHO-DD]
Common Name English
MAGNESIUM ASPARTATE [II]
Common Name English
MAGNESIUM ASPARTATE TETRAHYDRATE
WHO-DD  
Systematic Name English
ASPARTIC ACID, L-, MAGNESIUM SALT (2:1), TETRAHYDRATE
Common Name English
ASPARTIC ACID, MAGNESIUM SALT (2:1), TETRAHYDRATE
Common Name English
MAGNESIUM ASPARTATE [MART.]
Common Name English
ASPARTIC ACID, MAGNESIUM SALT
Common Name English
MAGNESATE(2-), BIS(L-ASPARTATO(2-)-N,O1)-, DIHYDROGEN, (.BETA.-4)-
Common Name English
L-ASPARTIC ACID, MAGNESIUM SALT, HYDRATE (2:1:4)
Common Name English
Classification Tree Code System Code
WHO-VATC QA12CC05
Created by admin on Sat Dec 17 11:20:46 UTC 2022 , Edited by admin on Sat Dec 17 11:20:46 UTC 2022
WHO-ATC A12CC05
Created by admin on Sat Dec 17 11:20:46 UTC 2022 , Edited by admin on Sat Dec 17 11:20:46 UTC 2022
Code System Code Type Description
LACTMED
Magnesium Aspartate
Created by admin on Sat Dec 17 11:20:46 UTC 2022 , Edited by admin on Sat Dec 17 11:20:46 UTC 2022
PRIMARY
EVMPD
SUB21949
Created by admin on Sat Dec 17 11:20:46 UTC 2022 , Edited by admin on Sat Dec 17 11:20:46 UTC 2022
PRIMARY
EVMPD
SUB14415MIG
Created by admin on Sat Dec 17 11:20:46 UTC 2022 , Edited by admin on Sat Dec 17 11:20:46 UTC 2022
PRIMARY
DAILYMED
R17X820ROL
Created by admin on Sat Dec 17 11:20:46 UTC 2022 , Edited by admin on Sat Dec 17 11:20:46 UTC 2022
PRIMARY
EPA CompTox
DTXSID60990418
Created by admin on Sat Dec 17 11:20:46 UTC 2022 , Edited by admin on Sat Dec 17 11:20:46 UTC 2022
PRIMARY
PUBCHEM
56841975
Created by admin on Sat Dec 17 11:20:46 UTC 2022 , Edited by admin on Sat Dec 17 11:20:46 UTC 2022
PRIMARY
NCI_THESAURUS
C1505
Created by admin on Sat Dec 17 11:20:46 UTC 2022 , Edited by admin on Sat Dec 17 11:20:46 UTC 2022
CONCEPT Dietary Supplement
ChEMBL
CHEMBL2104827
Created by admin on Sat Dec 17 11:20:46 UTC 2022 , Edited by admin on Sat Dec 17 11:20:46 UTC 2022
PRIMARY
CAS
7018-07-7
Created by admin on Sat Dec 17 11:20:46 UTC 2022 , Edited by admin on Sat Dec 17 11:20:46 UTC 2022
PRIMARY
DRUG BANK
DB13359
Created by admin on Sat Dec 17 11:20:46 UTC 2022 , Edited by admin on Sat Dec 17 11:20:46 UTC 2022
PRIMARY
CAS
14433-91-1
Created by admin on Sat Dec 17 11:20:46 UTC 2022 , Edited by admin on Sat Dec 17 11:20:46 UTC 2022
ALTERNATIVE
RXCUI
142131
Created by admin on Sat Dec 17 11:20:46 UTC 2022 , Edited by admin on Sat Dec 17 11:20:46 UTC 2022
PRIMARY RxNorm
ChEMBL
CHEMBL2109228
Created by admin on Sat Dec 17 11:20:46 UTC 2022 , Edited by admin on Sat Dec 17 11:20:46 UTC 2022
PRIMARY
FDA UNII
R17X820ROL
Created by admin on Sat Dec 17 11:20:46 UTC 2022 , Edited by admin on Sat Dec 17 11:20:46 UTC 2022
PRIMARY
NCI_THESAURUS
C76080
Created by admin on Sat Dec 17 11:20:46 UTC 2022 , Edited by admin on Sat Dec 17 11:20:46 UTC 2022
PRIMARY
DRUG CENTRAL
4517
Created by admin on Sat Dec 17 11:20:46 UTC 2022 , Edited by admin on Sat Dec 17 11:20:46 UTC 2022
PRIMARY
WIKIPEDIA
MAGNESIUM ASPARTATE
Created by admin on Sat Dec 17 11:20:46 UTC 2022 , Edited by admin on Sat Dec 17 11:20:46 UTC 2022
PRIMARY
Related Record Type Details
Structure of ASPARTIC ACID
PARENT -> SALT/SOLVATE
Structure of MAGNESIUM ASPARTATE ANHYDROUS
ANHYDROUS->SOLVATE
Related Record Type Details
Structure of MAGNESIUM CATION
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966